Ensysce Biosciences (ENSC) vs MetaVia (MTVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ensysce Biosciences is the larger company by market cap ($8.9 million vs $8.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENSC | MTVA |
|---|---|---|
| Share price | $0.458 | $1.34 |
| Market cap | $8.91M | $8.83M |
| 1-day change | +6.66% | -8.22% |
| EPS (TTM) | $-2.47 | $-3.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.75 | $14.85 |
| 52-week low | $0.23 | $0.966 |
| Distance from 52-week high | -83.35% | -90.98% |
| Analyst consensus | none | none |
| Avg. price target upside | +1701.31% | +1342.54% |
| Average volume | 14.21M | 228.48K |
| Shares outstanding | 19.46M | 6.59M |
| Employees | 8 | 8 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ensysce Biosciences
ENSC stock →Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.
Healthcare · Biotechnology · 8 employees
About MetaVia
MTVA stock →MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity.
Healthcare · Biotechnology · 8 employees
ENSC vs MTVA FAQ
Which is bigger, Ensysce Biosciences or MetaVia?
Ensysce Biosciences (ENSC) is larger, with a market capitalization of $8.91M compared with $8.83M for MetaVia (MTVA).
Are Ensysce Biosciences and MetaVia in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.